Faculty Profiles - MATSUSHITA, Tadashi

Papers - MATSUSHITA, Tadashi

Division display 61 - 80 of about 231 ／ All the affair displays >>

*Fatal thrombosis of antithrombin-deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor mice Reviewed

Hayashi, M., Matsushita, T., Mackman, N., Ito, M., Adachi, T., Katsumi, A., Yamamoto, K., Takeshita, K., Kojima, T., Saito, H., Murohara, T. and Naoe, T.

Journal of Thrombosis and Haemostasis Vol. 4 ( 1 ) page： 177-185 2006

Language：English Publishing type：Research paper (scientific journal)

Summary. Background: We previously reported that the targeted disruption of murine antithrombin (AT) gene resulted in embryonic lethality before 16.5 gestational days (gd) because of severe cardiac and hepatic thrombosis. Objective and Methods: To investigate the influences of lowered tissue factor (TF) activity upon hypercoagulation of AT-/- embryos, we crossed AT+/- with low TF (mTF-/-hTF+) mice to yield homozygous AT-deficient mice with the extremely low TF activity, that is expressed from the inserted human TF mini gene. Results: AT-/- embryos either with 50% TF (AT-/-mTF+/-hTF+) or with low (~1% TF, AT-/-mTF-/-hTF+) were not born, although the survival was prolonged until 18.5 gd. In both genotypes, histological examination showed disseminated thrombosis in hepatic sinusoidal space or in the portal veins, suggesting that the thrombogenesis caused loss of hepatic blood flow. As in original AT-/-, AT-/-mTF+/-hTF+ showed subcutaneous (s.c.) bleeding and also suffered from the myocardial degeneration apparently because of coronary thrombus formation. However, AT-/-mTF-/-hTF+ had no skin hemorrhage and the thrombosis and degeneration were completely abolished in the heart. Myocardium of adult low TF mice had exhibited fibrosis secondary to hemorrhage; however, it was significantly decreased in low TF mice with AT+/-. Conclusions: Our current model suggests that, in the heart, TF plays an important role in the thrombogenesis and it counterbalances AT-dependent anticoagulation. AT may be a potent anticoagulant during mice development and the activation and subsequent regulation of TF-procoagulant activity take place differently between the liver and the heart. These differences appear to point to local regulatory mechanisms in murine hemostasis.

Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin Reviewed

"Yamamoto, K., Honda, T., Matsushita, T., Kojima, T. and Takamatsu, J."

J Thromb Haemost Vol. 4 ( 2 ) page： 469-70 2006

Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No, but they need a careful look Invited

Matsushita, T. and Saito, H.

J Thromb Haemost Vol. 4 ( 9 ) page： 2066-7 2006.9

"[Approaches to anemia, thrombocytopenia, and DIC in cancer patients]" Reviewed

"Matsushita, T."

Gan To Kagaku Ryoho Vol. 33 ( 1 ) page： 6-12 2006

Language：English Publishing type：Research paper (scientific journal)

"Patients with cancer-related anemia have an inadequate Epo response that is further impaired by cancer treatments such as chemotherapy. Significant number of studies have demonstrated that treatment of anemia in cancer patients using recombinant human EPO(rHuEPO, epoetin alfa) significantly increases hemoglobin(Hb) levels,reduces transfusion requirements,and improves quality of life,particularly by relieving fatigue. However,the findings of several studies have raised the possibility of an adverse effect of thromboembolism. The American Society of Clinical Oncology and the American Society of Hematology developed an evidence-based clinical practice guideline for the use of epoetin in patients with cancer. In cancer patients, the risk of bleeding depends not only on the platelet count, but also on the underlying disease, in accordance with coagulation defects. The cause of thrombocytopenia must be established prior to platelet transfusion since platelet transfusions may be relatively contraindicated in certain conditions e. g., heparin-induced thrombocytopenia(HIT), and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome(TTP/HUS)."

Classic polyarteritis nodosa presenting rare clinical manifestations in a hemophilia A patient Reviewed

"Matsushita, T., Adachi, H., Watanabe, H., Shimoyama, Y., Adachi, T., Sobue, G., Ito, M., Kojima, T., Saito, H. and Naoe, T."

Int. J. Hematol Vol. 83 page： 420-425 2006

Recurrent Intramural Hematoma of the Small Intestine in a Severe Hemophilia A Patient with a High Titer of Factor VIII Inhibitor: A Case Report and Review of the Literature Reviewed

Katsumi, A., Matsushita, T., Hirashima, K., Iwasaki, T., Adachi, T., Yamamoto, K., Kojima, T., Takamatsu, J., Saito, H. and Naoe, T.

Int J Hematol Vol. 84 ( 2 ) page： 166-9 2006

Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor. Reviewed

Adachi T, Matsushita T, Dong Z, Katsumi A, Nakayama T, Kojima T, Saito H, Sadler JE, Naoe T.

Biochem Biophys Res Commun Vol. 339 page： 1178-83 2006

In vitro characterization of missense mutations associated with quantitative protein S deficiency Reviewed

Okada, H., Yamazaki, T., Takagi, A., Murate, T., Yamamoto, K., Takamatsu, J., Matsushita, T., Naoe, T., Kunishima, S., Hamaguchi, M., Saito, H. and Kojima, T.

Journal of Thrombosis and Haemostasis Vol. 4 ( 9 ) page： 2003-2009 2006

High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogenic hematopoietic stem cell transplantation Reviewed

"Adachi, T., Matsushita, T., Ichihashi, R., Hirashima, K., Ito, M., Inukai, A., Yokozawa, T., Nishida, T., Murata, M., Hayashi, M., Katsumi, A., Kojima, T., Saito, H. and Naoe, T."

Int. J. Hematol. Vol. 83 page： 415-419 2006

Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Reviewed

1. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T.

Eur J Haematol Vol. 78 page： 213-219 2007

Molecular basis of antithrombin deficiency in four Japanese patients with antithrombin gene abnormalities including two novel mutations. Reviewed

Kyotani M, Okumura K, Takagi A, Murate T, Yamamoto K, Matsushita T, Sugimura M, Kanayama N, Kobayashi T, Saito H, Kojima T.

Am J Hematol. Vol. 82 ( 8 ) page： 702-705 2007.8

Pitavastatin attenuates the upregulation of tissue factor in restraint-stressed mice. Reviewed

Yamamoto K, Kojima T, Takeshita K, Matsushita T, Takamatsu J.

Thromb Res 2007 Vol. 2007 page： 143-144 2007

An Sp1 binding site mutation of the PROS1 promoter in a patient with protein S deficiency. Reviewed

Sanda N, Fujimori Y, Kashiwagi T, Takagi A, Murate T, Mizutani E, Matsushita T, Naoe T, Kojima T.

Br J Haematol 2007 Vol. 138 page： 663-666 2007

Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations. Reviewed

Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, Hamaguchi M, Saito H.

Eur J Haematol. Vol. 78 ( 3 ) page： 220-226 2007

Prognostic analysis of aberrant somatic hypermutation of RhoH gene in diffuse large B cell lymphoma. Reviewed

Hiraga J, Katsumi A, Iwasaki T, Abe A, Kiyoi H, Matsushita T, Kinoshita T, Naoe T.

Leukemia. Vol. 21 ( 8 ) page： 1846-1847 2007

Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. Reviewed

Fontayne A, De Maeyer B, De Maeyer M, Yamashita M, Matsushita T, Deckmyn H.

Vol. 282 ( 32 ) page： 23517-23524 2007

A neonate with homozygous protein C deficiency with a homozygous Arg178Trp mutation. Reviewed

Ozlu F, Kyotani M, Taskin E, Ozcan K, Kojima T, Matsushita T, Yapicioğlu H, Takagi A, Saşmaz I, Satar M, Narli N

J Pediatr Hematol Oncol Vol. 30 page： 608-611 2008

A new binding assay of von Willebrand factor and glycoprotein Ib using solid-phase biotinylated platelets.

Hayata K, Nakayama T, Matsushita T, Sakano K

J Pharmacol Sci. Vol. 108 page： 217-221 2008

Mutational analysis of SOS1 gene in acute myeloid leukemia. Reviewed

Tanizaki R, Katsumi A, Kiyoi H, Kunishima S, Iwasaki T, Ishikawa Y, Kobayashi M, Abe A, Matsushita T, Watanabe T, Kojima T, Kaibuchi K, Kojima S, Naoe T.

Int J Hematol. Vol. 88 page： 460-462 2008

Identification and characterization of the first large deletion of the MYH9 gene associated with MYH9 disorders. Reviewed

Kunishima S, Matsushita T, Hamaguchi M, Saito H

Eur J Haematol. Vol. 80 page： 540-544 2008

　 PREV - NEXT 　

<MATSUSHITA, Tadashi>

Papers - MATSUSHITA, Tadashi